INNOPHLEX
LIVE

Serial Number

79236788

Owner

PharmaLex GmbH

Filing Date

Jan 12, 2018

Add to watchlist:

No watchlists yet
View on USPTO

INNOPHLEX Trademark

Serial Number: 79236788 • Registration: 5893636

INNOPHLEX is a trademark filed by PharmaLex GmbH on January 12, 2018. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PharmaLex GmbH (10 trademarks)

Bahnstrasse 42-46

Entity Type: 99

Trademark Details

Filing Date

January 12, 2018

Registration Date

October 29, 2019

Published for Opposition

August 13, 2019

Cancellation Date

May 15, 2026

Goods & Services

Advertising services, business management for others, company administration in the nature of business administration services; providing office functions; business efficiency expert services; systemization of information into computer databases; compilation of information into computer databases; business assistance and consultancy in the context of the retailing and wholesaling of medicines; providing of outsourcing services in the field of business management for companies engaged in the field of medicine authorization, production, sale, safety and monitoring; regulatory submission management, namely, filing of documents for authorizing medicines using documents, reports and files required by regulatory authorities; administrative assistance and consultancy in the nature of preparation and filing of applications for pharmaceutical medicine approval with governmental regulatory bodies

Providing pharmaceutical and medical assistance and consultancy during an initial application process of marketing authorization or product approval for pharmaceutical companies; provision of medical and pharmaceutical advice and expertise for pharmaceutical companies; providing information relating to the preparation and dispensing of medications; provision of pharmaceutical information; provision of information relating to medicine; consultancy and information services provided via the internet relating to pharmaceutical products; consultancy and information services relating to pharmaceutical products; consultancy and information services relating to biopharmaceutical products; advisory services relating to pharmaceuticals; medical services, medical diagnostic services; medical services, medical diagnostic services and pharmaceutical advisory services and consultancy in the field of medicine safety

Scientific and technological services and research and design relating thereto, namely, scientific research, laboratory research in the field of pharmaceuticals; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services; research and development of new products for others; provision of surveys, namely, medical research surveys; software development services, namely, development of a web application for inputting and using informative texts for medicines and medical products, in particular user guides, packaging inserts, specialist information, and for providing various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; research in relation to scientific work; preparation of scientific analysis and assessments; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing; pharmaceutical products development; development of pharmaceutical preparations and medicines; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical drug development services; medical laboratory services; information technology advisory, consultancy and information services for the pharmaceutical and healthcare industries; scientific assessment of the efficiency of medicines; services for assessing the efficiency of pharmaceuticals being pharmaceutical product evaluation; analysis and evaluation of product design; analysis and evaluation of product development; quality control testing for others; materials testing and evaluation; product safety testing; quality control services, namely, testing, analysis and evaluation of the services of others to determine conformity with certification standards; quality testing of products for certification purposes; assistance and consultancy in the nature of pharmaceutical research in the field of medicine safety and monitoring; pharmaceutical drug development consultancy in the field of medicine safety

Filing History

CANCELLED SECTION 71
May 15, 2026 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Nov 15, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 29, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 18, 2022 NREP
NEW REPRESENTATIVE AT IB RECEIVED
May 21, 2020 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 6, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 19, 2020 FICS
FINAL DISPOSITION PROCESSED
Feb 19, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 29, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 29, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2019 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Aug 9, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 24, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 24, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 9, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 8, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 8, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 15, 2019 GNFN
FINAL REFUSAL E-MAILED
Jan 15, 2019 GNFR
FINAL REFUSAL WRITTEN
Jan 15, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 22, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2018 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 22, 2018 CHAN
ASSIGNED TO LIE
Dec 22, 2018 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 19, 2018 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 19, 2018 TROA
REFUSAL PROCESSED BY IB
Sep 1, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 13, 2018 RFCS
REFUSAL PROCESSED BY MPU
Aug 13, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 31, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jul 30, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Jul 27, 2018 MAFR
ASSIGNED TO EXAMINER
Jul 23, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 23, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 19, 2018 REPR